Search
Charles River Laboratories International Inc
CRLAdd to Watchlist
234.300USD
-0.500-0.21%
Close 07-29 16:00（ET）Quotes delayed by 15 min
11.29BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-29The current earnings forecast score of Charles River Laboratories International Inc is 7.89, ranking 271 out of 384 in the Biotechnology & Medical Research industry. The average price target is 197.00, with a high of 211.00 and a low of 157.42.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
231.445
Target Price
+3.19%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Charles River Laboratories International Inc
CRL
19
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Charles River Laboratories International Inc's expected revenue for the next quarter?
Charles River Laboratories International Inc's expected revenue is 974.72M.
What is Charles River Laboratories International Inc's price target?
Analysts forecast that Charles River Laboratories International Inc's price target is USD 197.00, with the highest forecast at USD 211.00 and the lowest forecast at USD 157.42.
How have Charles River Laboratories International IncCRL's recent earnings per share performed?
The market expectation was USD -0.30, while Charles River Laboratories International IncCRL's earnings per share (EPS) for the previous quarter was USD -5.62. EPS for the next quarter is expected at USD 2.73.
What is the analyst rating for Charles River Laboratories International Inc?
Based on the ratings of Charles River Laboratories International Inc's stock from 19 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.